Aprogen Medicines Inc. announced a private placement of series 29 bearer-type non-guaranteed private convertible bonds for a gross proceeds of KRW 70,000,000,000 on September 8, 2023. The transaction has been approved by the board of directors of the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,307 KRW | -3.47% | -11.81% | +36.15% |
1st Jan change | Capi. | |
---|---|---|
+36.15% | 244M | |
+24.84% | 6.53B | |
+1.50% | 3.07B | |
-4.40% | 2.58B | |
-15.77% | 1.6B | |
+0.70% | 1.09B | |
-35.04% | 842M | |
+5.69% | 660M | |
-32.37% | 646M | |
+8.31% | 578M |
- Stock Market
- Equities
- A007460 Stock
- News Aprogen Medicines Inc.
- Aprogen Medicines Inc. announced that it expects to receive KRW 70 billion in funding